Research progress of tralokinumab for the treatment of moderate and severe atopic dermatitis
10.3760/cma.j.cn341190-20220118-00046
- VernacularTitle:曲罗芦单抗治疗中重度特应性皮炎的研究进展
- Author:
Jingui ZHANG
1
;
Chao WANG
Author Information
1. 海南省人民医院I期临床试验病房,海口 570311
- Keywords:
Dermatitis,atopic;
Chemistry,pharmaceutical;
Clinical study;
Pharmacokinetics;
Absorption,physicochemical;
Biotransformation;
Drug-related side effects and
- From:
Chinese Journal of Primary Medicine and Pharmacy
2024;31(3):474-476
- CountryChina
- Language:Chinese
-
Abstract:
Tralokinumab is a selective interleukin-13 inhibitor developed by LEO Pharma in Denmark. It was granted approval by the US Food and Drug Administration on December 27, 2021, for the treatment of patients aged 18 years or older with moderate to severe atopic dermatitis whose disease is refractory to or cannot be fully controlled by local prescription therapy. This article presents a comprehensive review of the recent research progress in the treatment of moderate to severe atopic dermatitis with tralokinumab.
